MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2025 International Congress

    Does the cerebellum compensate to enable motor learning in Parkinson’s Disease?

    PC. Iyer, BE. Fisher (Los Angeles, USA)

    Objective: To test the causal relation between cerebellar function and learning in PD. Background: Neuroimaging studies reveal that people with Parkinson’s disease (PwPD) exhibit increased…
  • 2025 International Congress

    Treatment Of Advanced Parkinson’s With Levodopa–Entacapone–Carbidopa Intestinal Gel – Impact On Dyskinesia

    B. Amlani, N. Smith (Reading, United Kingdom)

    Objective: To evaluate the effect of long-term treatment with levodopa–entacapone–carbidopa intestinal gel (LECIG) infusion on daily time with dyskinesia in people with advanced Parkinson’s disease…
  • 2025 International Congress

    Safinamide as an Adjunct Therapy for Motor Symptoms and ON-Time Extension in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    A. Fornari Caprara, J. Pitton Rissardo (Camden, USA)

    Objective: To evaluate the efficacy of safinamide as an adjunct therapy in improving motor symptoms and extending ON-time in patients with Parkinson’s disease (PD). Background:…
  • 2025 International Congress

    A case of Parkinson’s Disease whose Daily Levodopa/Carbidopa Intestinal Gel dose has been determined by her spouse and prevented Long-term Fluctuations

    Y. Okuma (Izunokuni, Japan)

    Objective: To present a case of Parkinson’s disease (PD) whose daily levodopa/carbidopa intestinal gel (LCIG) dose has been determined by her spouse and prevented long-term…
  • 2025 International Congress

    Mucuna pruriens for FOG in Parkinson’s disease, Do we have a solution for this trivial problem?

    M. Matta, N. Sawal, S. Singh, K. Verma, S. Sharma (Chandigarh, India)

    Objective: To study the effects of Mucuna Pruriens when administered via inhalation route,  to alleviated symptoms of Parkinson's disease most importantly freezing of gait. Background: Mucuna…
  • 2025 International Congress

    Effect of COVID-19 Pandemic on Utilization of Parkinson’s Medications in Saudi Arabia: A Repeated Cross-Sectional Study

    K. Orayj (Abha, Saudi Arabia)

    Objective: This study aims to examine the effects of the pandemic on the patterns of medication usage for Parkinson’s Disease (PD) in Saudi Arabia. Background:…
  • 2025 International Congress

    Platelets Lipidome as Potential Biomarker of Parkinson’s Disease

    G. Uras, S. Lucas-Del-Pozo, V. Lentini, F. Fierli, S. Koletsi, D. Hughes, A. Schapira, . (London, United Kingdom)

    Objective: The aim of this proejct is to identify novel biomarkers of Parkinson's disease diagnosis and progression, with a focus on GBA-PD. Background: Our previous…
  • 2025 International Congress

    Paradoxical Association of Kinetics of α-Synuclein Seed Amplification 24-hrs Assay and Clinico-Pathological Markers of Parkinson’s disease

    SM. Fereshtehnejad, Y. Zeighami, C. Marras (TORONTO, Canada)

    Objective: To investigate the association between baseline α-synuclein seed amplification assay (SAA) parameters and clinical and biomarker features of Parkinson’s disease (PD) at baseline and…
  • 2025 International Congress

    Eye movement abnormalities in GBA1-related Parkinson’s disease and non-manifesting GBA1-carriers

    G. Riboldi, T. Hudson, H. Conn, K. Astudillo, J. Rizzo, S. Frucht, J. Rucker (New York, USA)

    Objective: To perform an in-depth characterization of eye movement abnormalities in Parkinson’s disease (PD) and non-manifesting carriers of GBA1 pathogenic variants. Background: Eye movement abnormalities…
  • 2025 International Congress

    Amplification Parameters of the Alpha-Synuclein Seed Amplification Assay on CSF Predict the Clinical Subtype of Parkinson’s Disease at 10-Year Follow-Up

    P. Grillo, GM. Riboldi, A. Pisani, UJ. Kang, SM. Fereshtehnejad (Pavia, Italy)

    Objective: To assess the association between the parameters of alpha-synuclein seed amplification assay on CSF (CSF-αSyn-SAA) within 2 years from Parkinson’s disease (PD) onset and…
  • « Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley